New stock news | Bausch Health Hong Kong Stock IPO prospectus invalid
BlissBio Inc. (referred to as Ba Lisikang) submitted its Hong Kong IPO prospectus on June 29th, which expired after 6 months on December 29th.
BlissBio Inc. (referred to as Baolisikang) submitted its Hong Kong IPO prospectus on June 29th, which expired after 6 months on December 29th, with Goldman Sachs, Huatai International, and CICC as joint sponsors.
The prospectus shows that BlissBio is a clinical-stage biopharmaceutical company dedicated to developing the next generation of antibody-drug conjugates (ADCs) to address important unmet needs in current cancer treatment. The company's core product, BB-1701, is a human epidermal growth factor receptor 2 (HER2)-targeting ado-trastuzumab emtansine (T-DM1) ADC candidate drug, primarily targeting breast cancer (BC), non-small cell lung cancer (NSCLC), and other potential HER2-expressing cancers.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
